Geeta Nair

The Serum Institute of India rapidly produced 620,000 doses of the ChAdOx1 Bundibugyo ebolavirus vaccine and supplied 4,000 doses for Oxford's Phase I trial to combat the Ebola outbreak in DRC and Uganda.

Novel drug discovery is gathering pace in India's life sciences sector as it looks beyond generics.

Bengaluru-based Curated Living Solutions (CLS) has debuted its "Hospitality Investment Plan" (HIP), a fractional ownership model targeting retail real estate investors. The launch coincides with a ₹200-crore mixed-use project in Pune backed by a 29-year master lease agreement.

Automotive components from Brakes India and Wheels India lead the first export consignment following the enforcement of the landmark UK-India trade agreement (CETA), driving growth prospects for India's ₹7.6 lakh crore auto parts sector.

The Gates Medical Research Institute and Serum Institute of India have signed an agreement to mass-produce the M72/AS01E tuberculosis vaccine candidate, potentially introducing the first new TB vaccine in over a century.

Tata Technologies posted an 11.4% sequential decline in net profit to ₹180.8 crore for Q1, impacted by a high base from a prior one-time provision reversal.

Emcure Pharmaceuticals expands the use of Poviztra, its GLP-1 drug semaglutide, to treat non-cirrhotic MASH, a progressive liver disease with limited options, following CDSCO approval for Wegovy.

Bajaj Auto reported a 42% rise in standalone net profit to Rs 2,983 crore in Q1, driven by strong domestic and export sales, improved product mix, and growing electric vehicle revenue amid capacity expansion plans.

Bajaj Group celebrates 100 years with a focus on adaptation, highlighting Bajaj Auto's shift to electric vehicles, global expansion, and innovative management to lead the future market.

GIFT City has cemented its position as a primary gateway for global capital, routing approximately 70% of external commercial borrowings (ECBs) in FY26.